Posted September 15, 2013 in Beauty, Blog, Botox and Facial Fillers, Uncategorized
In a press release last week, Allergan, the manufacturer of the neuromodulator Botox announced, “Allergan, Inc., (NYSE: AGN) today announced approval by the U.S. Food and Drug Administration (FDA) 
to market BOTOX® Cosmetic (onabotulinumtoxinA), for an additional indication to temporarily treat moderate to severe lateral canthal lines, commonly known as “crow’s feet” lines. BOTOX® Cosmetic is the first and only product of its kind approved for this indication.” We have been 
using Botox, as well as the other available neuromodulators Dysport and Xeomin, for the treatment of crow’s feet for many years “off label”. A study performed by researchers including Corey Maas, MD actually concluded that when Dysport was used on one side and Botox on the other side, people thought that the Dysport side looked better over time.
To see the full press release go to ://links.allergan.mkt829.com/servlet/MailView?ms=NDI1OTcxNjgS1&r=NjcxNDkzODU3MTQS1&j=MjAzMDQ5MTUwS0&mt=1&rt=0
Dr. Michael Persky and Dr. Sarmela Sunder are located in Encino, California and Beverly Hills, California but service all of Los Angeles and the San Fernando Valley. Including, Beverly Hills, Hollywood, Hancock Park, Brentwood, Santa Monica, Pacific Palisades, Malibu, Sherman Oaks, Studio City, Calabasas, Woodland Hills, Tarzana, Westlake, Thousand Oaks, Agoura Hills, La Canada, Pasadena, and more. Please subscribe to our blog by clicking the link above, right, and “Like” us on Facebook. Thank you! + Michael Persky
